Endometrial
Oncology
Prevalence
58.0 / 100K
Incidence
28.0 / 100K/yr
37 drugs in development·27 companies·2 clinical trials
Drug Pipeline by Phase
Approved(3)
Phase 3(11)
Phase 2(6)
Phase 1(7)
Preclinical(3)
Unknown(1)
| Drug | Company |
|---|---|
| MyRisk | MYRIAD GENETICS INC (MYGN) |
Early Phase 1(1)
| Drug | Company |
|---|---|
| Dendritic Cell Vaccine | Merus N.V. (MRUS) |
Phase 1/Phase 2(4)
Phase 4(1)
| Drug | Company |
|---|---|
| Tirzepatide | ENANTA PHARMACEUTICALS INC (ENTA) |
Compare drugs
Frequently asked questions
How many drugs are in development for Endometrial?
BioSniper tracks 37 drugs in development for Endometrial across 27 companies.
How many clinical trials target Endometrial?
There are 2 clinical trials targeting Endometrial tracked by BioSniper.
What is the prevalence of Endometrial?
The estimated prevalence of Endometrial is approximately 58.0 per 100,000 population.
Deep-dive into Endometrial
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis